China’s National Medical Products Administration approved Innovent Biologics’ Tabosun (ipilimumab N01, IBI‑310) in combination with sintilimab as a neoadjuvant treatment for stage IIB–III resectable MSI‑high or mismatch repair‑deficient colon cancer. The approval makes Tabosun one of the first domestically developed CTLA‑4 monoclonal antibodies to secure an NMPA nod and expands neoadjuvant immunotherapy options for a genetically defined colon cancer population.